Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS: ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients received up to ten 21-day cycles of doc...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon J., Griffiths, Gareth, Marwood, Ellice, Dunkley, Denise, Downs, Nichola, Martin, Karen, Light, Michelle, Northey, Josh, Wilding, Sam, Whitehead, Amy, Shaw, Emily, Birtle, Alison J., Bahl, Amit, Elliott, Tony, Westbury, Charlotte, Sundar, Santhanam, Robinson, Angus, Jagdev, Satinder, Kumar, Satish, Rooney, Claire, Salinas-Souza, Carolina, Stephens, Christine, Khoo, Vincent, Jones, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078455/
https://www.ncbi.nlm.nih.gov/pubmed/33326257
http://dx.doi.org/10.1200/JCO.20.01576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078455/
https://www.ncbi.nlm.nih.gov/pubmed/33326257
http://dx.doi.org/10.1200/JCO.20.01576

Ejemplares similares